US 8,298,784 B2Granted

In vitro procedure for diagnosis and early diagnosis of neurodegenerative diseases

AssigneeB.R.A.H.M.S GmbH

InventorsAndreas Bergmann, Andrea Ernst, Harald Hampel

Life of this patent

Estimating the term…

Loading patent…

Abstract

An in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurogenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the determination of the analyte is performed directly and/or indirectly as the determination of a relevant co-peptide generated from a mutual propeptide, and is based upon the measured concentration of the determined analyte thus making it possible to form conclusions about a neurodegenerative disease or an early form typical of such a disease or the course of the disease and/or the success of the efforts to relieve or prevent the disease.

Claims4

Dependent claims

A method for assisting in the early detection of Alzheimer's disease, the method comprising:

(a) contacting a blood, plasma or serum sample obtained from a patient in whom Alzheimer's disease (AD) is suspected with first and second antibodies, each of which specifically binds to a peptide consisting of the amino acids sequence PEVPPWTGEVSPAQRDGGALGRGPWDSSDRSALLKSKL (SEQ ID NO:
1), wherein said first and second antibodies bind to a pro-atrial naturiuretic peptide (pro-ANP) peptide comprising the amino acids sequence PEVPPWTGEVSPAQRDGGALGRGPWDSSDRSALLKSKL (SEQ ID NO:
1) in said sample to form labeled immunocomplexes of pro-ANP and first and second antibodies and wherein at least one of said first and second antibodies comprises a detectable label;
and
(b) determining the amount of immunocomplex-associated detectable label in the blood, plasma or serum sample, wherein the amount of detectable label in said sample correlates to the amount of pro-ANP in the sample,
wherein, if the amount of pro-ANP in said sample is equal to or greater than 87.0 pmol/L, Alzheimer's disease is indicated.

3 more elements

Dependencies are inferred from the claim text.